Misplaced Pages

KP-1461

Clinical data
Drug class	Reverse transcriptase inhibitor
Legal status
Legal status	Investigational
Identifiers
CAS Number	815588-85-3
PubChem CID	51003457
DrugBank	05644
ChemSpider	32702166
UNII	3PEN569TJP
CompTox Dashboard (EPA)	DTXSID101112194
Chemical and physical data
Formula	C16H23N4O6
Molar mass	367.382 g·mol
3D model (JSmol)	Interactive image
SMILES CCCCCCCOC(=O)NC1=NCN(C(=O)N1)2C((O2)CO)O
InChI InChI=1S/C16H28N4O6/c1-2-3-4-5-6-7-25-16(24)19-14-17-10-20(15(23)18-14)13-8-11(22)12(9-21)26-13/h11-13,21-22H,2-10H2,1H3,(H2,17,18,19,23,24)/t11-,12+,13+/m0/s1 Key:SZWIAFVYPPMZML-YNEHKIRRSA-N

KP-161 is an experimental antiviral drug being studied for the treatment of HIV/AIDS. It belongs to the class of nucleoside reverse transcriptase inhibitors.

KP-1461 is a prodrug of the active antiviral agent KP-1212.

References

1. "KP-1461". AIDSinfo. U.S. Department of Health and Human Services. Archived from the original on 2019-08-11. Retrieved 2018-09-04.
2. Harris K, Sergueev D, Reno J (December 2006). "The chemistry and biology of KP-1461, a selective nucleoside mutagen for HIV therapy". Retrovirology. 3 (Suppl 1): S13. doi:10.1186/1742-4690-3-S1-S13. PMC 1716920.
3. "KP-1461". DrugBank. Canadian Institutes of Health Research.

This antiinfective drug article is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Reverse transcriptase inhibitors
• Experimental drugs
• Prodrugs
• Antiinfective agent stubs